SDF-1 inhibition targets the bone marrow niche for cancer therapy

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Bone marrow (BM) metastasis is a major cause of mortality in solid tumors and multiple myeloma (MM).
• Current strategies to target the BM niche for metastasis prevention have yielded limited success.
• Stromal cell-derived factor-1 (SDF-1/CXCL12) is significantly upregulated in active MM and BM sites of metastasis.

Purpose of the Study:

• To investigate the role of SDF-1 in MM bone marrow colonization.
• To evaluate the efficacy of neutralizing SDF-1 using a novel anti-SDF-1 agent, olaptesed-pegol, in preclinical models of MM.

Main Methods:

• In vivo confocal imaging to visualize SDF-1 levels in MM-colonized BM areas.
• Utilized murine and xenograft mouse models to assess the impact of in vivo SDF-1 neutralization.
• Administered olaptesed-pegol to neutralize SDF-1 within the BM microenvironment.

Main Results:

• SDF-1 levels were found to be elevated in BM areas colonized by MM cells.
• Neutralization of SDF-1 in vivo resulted in a BM microenvironment less conducive to MM cell survival and growth.
• Inhibition of MM cell homing and growth was observed, leading to reduced disease progression.

Conclusions:

• Targeting SDF-1 is a promising strategy for preventing or disrupting bone marrow colonization by MM cells.
• Neutralization of SDF-1 effectively inhibits multiple myeloma progression within the bone marrow niche.
• Olaptesed-pegol demonstrates potential as a therapeutic agent for MM by targeting the SDF-1 pathway.